FDA commissioner Scott Gottlieb said the agency is concerned with companies making claims about the plant’s ability to treat opioid withdrawal and addiction, as well as other serious medical conditions.
In examining nearly 40 million blood pressure tests across higi’s network of more than 11,000 health stations in 2017, the company found a 28.8% increase in patients with high blood pressure.
Grifols has received the green light from the FDA for a new formulation of its Gamastan immune globulin (human) that uses a caprylate chromatography process.